Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. (9th February 2015)

• Record Type: Journal Article
• Authors: Elia, A. E.; Lalli, S.; Monsurrò, M. R.; Sagnelli, A.; Taiello, A. C.; Reggiori, B.; La Bella, V.; Tedeschi, G.; Albanese, A.
• Is Part Of: European journal of neurology. Volume 23:Number 1(2016:Jan.)
• Page Start: 45
• Page End: 52
• Publication Date: 2015-02-09
• Subjects: amyotrophic lateral sclerosis -- cholic acids -- tauroursodeoxycholic acid; Neurology -- Periodicals; Nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ene.12664
• Languages: English
• ISSNs: 1351-5101

Abstract

Abstract : Background and purpose: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produced in the liver and used for treatment of chronic cholestatic liver diseases. Experimental studies suggest that TUDCA may have cytoprotective and anti‐apoptotic action, with potential neuroprotective activity. A proof of principle approach was adopted to provide preliminary data regarding the efficacy and tolerability of TUDCA in a series of patients with amyotrophic lateral sclerosis (ALS). Methods: As a proof of principle, using a double‐blind placebo controlled design, 34 ALS patients under treatment with riluzole who were randomized to placebo or TUDCA (1 g twice daily for 54 weeks) were evaluated after a lead‐in period of 3 months. The patients were examined every 6 weeks. The primary outcome was the proportion of responders [those subjects with improvement of at least 15% in the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS‐R) slope during the treatment period compared to the lead‐in phase]. Secondary outcomes included between‐treatment comparison of ALSFRS‐R at study end, comparison of the linear regression slopes for ALSFFRS‐R mean scores and the occurrence of adverse events. Results: Tauroursodeoxycholic acid was well tolerated; there were no between‐group differences for adverse events. The proportion of responders was higher under TUDCA (87%) than under placebo ( P = 0.021; 43%). At study end baseline‐adjusted ALSFRS‐R was significantly higher ( P = 0.007) in TUDCA than in placebo groups. Comparison of the slopes of regression analysis showed slower progression in the TUDCA than in the placebo group ( P < 0.01). Conclusions: This pilot study provides preliminary clinical data indicating that TUDCA is safe and may be effective in ALS. Abstract : Clickhere to view the accompanying paper in this issue.